Details of the Drug

General Information of Drug (ID: DMZVMKF)

Drug Name
Alfuzosin
Synonyms
Alfusosine; Alfuzosina; Alfuzosine; Alfuzosinum; Alphuzosine; Alfuzosina [Spanish]; Alfuzosine [French]; Alfuzosinum [Latin]; Alfuzosin (INN); Alfuzosin [INN:BAN]; Xatral (TN); N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide; N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide; N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}tetrahydrofuran-2-carboxamide
Indication
Disease Entry ICD 11 Status REF
Benign prostatic hyperplasia GA90 Approved [1]
Multiple sclerosis 8A40 Approved [2]
Urinary retention MF50.3 Approved [2]
Therapeutic Class
Antihypertensive Agents
Affected Organisms
Humans and other mammalsMouseRat
ATC Code
G04CA01: Alfuzosin
G04CA: Alpha-adrenoreceptor antagonists
G04C: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
G04: UROLOGICALS
G: GENITO URINARY SYSTEM AND SEX HORMONES
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 389.4
Logarithm of the Partition Coefficient (xlogp) 1.7
Rotatable Bond Count (rotbonds) 8
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 194 mcgh/L [3]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 13.6 mcg/L [3]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 8 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability
The bioavailability of drug is 64% [3]
Clearance
The renal clearance of drug is 30 mL/min [3]
Elimination
Following oral administration of a radiolabeled alfuzosin solution, the detection of radioactivity after one week was 69% in the feces and 24% in the urine [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 10 hours [3]
Metabolism
The drug is metabolized via the hepatic [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.3354 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.14% [6]
Vd
The volume of distribution (Vd) of drug is 3.2 L/kg [3]
Chemical Identifiers
Formula
C19H27N5O4
IUPAC Name
N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide
Canonical SMILES
CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC
InChI
InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23)
InChIKey
WNMJYKCGWZFFKR-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2092
ChEBI ID
CHEBI:51141
CAS Number
81403-80-7
UNII
90347YTW5F
DrugBank ID
DB00346
TTD ID
D09MWJ
VARIDT ID
DR01382
ACDINA ID
D00018
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor alpha-1D (ADRA1D) TT34BHT ADA1D_HUMAN Antagonist [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [8]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Alpha-1A adrenergic receptor (ADRA1A) OTUIWCL5 ADA1A_HUMAN Protein Interaction/Cellular Processes [9]
Alpha-1B adrenergic receptor (ADRA1B) OTSAYAFD ADA1B_HUMAN Protein Interaction/Cellular Processes [10]
Alpha-1D adrenergic receptor (ADRA1D) OTW2CD1O ADA1D_HUMAN Protein Interaction/Cellular Processes [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Alfuzosin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Terazosin DM3JCVS Moderate Additive hypotensive effects by the combination of Alfuzosin and Terazosin. Prostate hyperplasia [GA90] [11]
Tamsulosin DM5QF9V Moderate Additive hypotensive effects by the combination of Alfuzosin and Tamsulosin. Prostate hyperplasia [GA90] [11]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Alfuzosin and Silodosin. Prostate hyperplasia [GA90] [11]
Coadministration of a Drug Treating the Disease Different from Alfuzosin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Alfuzosin and Ivosidenib. Acute myeloid leukaemia [2A60] [12]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Midostaurin. Acute myeloid leukaemia [2A60] [13]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Idarubicin. Acute myeloid leukaemia [2A60] [13]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Daunorubicin. Acute myeloid leukaemia [2A60] [13]
Gilteritinib DMTI0ZO Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Gilteritinib. Acute myeloid leukaemia [2A60] [14]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Oliceridine. Acute pain [MG31] [13]
Tacrine DM51FY6 Moderate Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Tacrine. Alzheimer disease [8A20] [13]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Rivastigmine. Alzheimer disease [8A20] [13]
Donepezil DMIYG7Z Moderate Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Donepezil. Alzheimer disease [8A20] [13]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Alfuzosin and Metronidazole. Amoebiasis [1A36] [15]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Alfuzosin and Bepridil. Angina pectoris [BA40] [13]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Alfuzosin and Dronedarone. Angina pectoris [BA40] [13]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Alfuzosin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [16]
Hydroxyzine DMF8Y74 Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [13]
Promazine DMZAL7W Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Promazine. Appearance/behaviour symptom [MB23] [13]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Cilostazol. Arterial occlusive disease [BD40] [13]
Voriconazole DMAOL2S Major Decreased metabolism of Alfuzosin caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [15]
Posaconazole DMUL5EW Major Decreased metabolism of Alfuzosin caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [15]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Levalbuterol. Asthma [CA23] [17]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Terbutaline. Asthma [CA23] [18]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Pirbuterol. Asthma [CA23] [18]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Salbutamol. Asthma [CA23] [17]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Formoterol. Asthma [CA23] [18]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [19]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Desipramine. Attention deficit hyperactivity disorder [6A05] [13]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Ofloxacin. Bacterial infection [1A00-1C4Z] [20]
Ciprofloxacin XR DM2NLS9 Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [13]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Alfuzosin caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [11]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Alfuzosin and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [13]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Alfuzosin and Sparfloxacin. Bacterial infection [1A00-1C4Z] [20]
Chloramphenicol DMFXEWT Moderate Decreased metabolism of Alfuzosin caused by Chloramphenicol mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [11]
Linezolid DMGFPU2 Moderate Additive hypotensive effects by the combination of Alfuzosin and Linezolid. Bacterial infection [1A00-1C4Z] [21]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Gemifloxacin. Bacterial infection [1A00-1C4Z] [20]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Levofloxacin. Bacterial infection [1A00-1C4Z] [20]
Troleandomycin DMUZNIG Major Decreased metabolism of Alfuzosin caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [15]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Lomefloxacin. Bacterial infection [1A00-1C4Z] [13]
Telithromycin DMZ4P3A Major Decreased metabolism of Alfuzosin caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [15]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Retigabine. Behcet disease [4A62] [13]
Cariprazine DMJYDVK Moderate Additive hypotensive effects by the combination of Alfuzosin and Cariprazine. Bipolar disorder [6A60] [22]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Loperamide. Bowel habit change [ME05] [23]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Lapatinib. Breast cancer [2C60-2C6Y] [13]
Tucatinib DMBESUA Major Decreased metabolism of Alfuzosin caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [15]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Alfuzosin and Toremifene. Breast cancer [2C60-2C6Y] [13]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Bosutinib. Breast cancer [2C60-2C6Y] [19]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Alfuzosin and Sotalol. Cardiac arrhythmia [BC9Z] [13]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [24]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Olodaterol. Chronic obstructive pulmonary disease [CA22] [18]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Vilanterol. Chronic obstructive pulmonary disease [CA22] [17]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Salmeterol. Chronic obstructive pulmonary disease [CA22] [18]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Indacaterol. Chronic obstructive pulmonary disease [CA22] [18]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Arformoterol. Chronic obstructive pulmonary disease [CA22] [18]
Oxaliplatin DMQNWRD Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Oxaliplatin. Colorectal cancer [2B91] [13]
Isoproterenol DMK7MEY Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Isoproterenol. Conduction disorder [BC63] [17]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Alfuzosin and Olopatadine. Conjunctiva disorder [9A60] [25]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Halothane. Corneal disease [9A76-9A78] [13]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Propofol. Corneal disease [9A76-9A78] [26]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Probucol. Coronary atherosclerosis [BA80] [13]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Clofazimine. Crohn disease [DD70] [27]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Alfuzosin and Pasireotide. Cushing syndrome [5A70] [13]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Osilodrostat. Cushing syndrome [5A70] [19]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Alfuzosin caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [28]
MK-8228 DMOB58Q Moderate Decreased metabolism of Alfuzosin caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [11]
Aprepitant DM053KT Moderate Decreased metabolism of Alfuzosin caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [11]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Sertraline. Depression [6A70-6A7Z] [13]
Trimipramine DM1SC8M Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Trimipramine. Depression [6A70-6A7Z] [13]
Imipramine DM2NUH3 Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Imipramine. Depression [6A70-6A7Z] [13]
Fluoxetine DM3PD2C Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Fluoxetine. Depression [6A70-6A7Z] [13]
Nortriptyline DM4KDYJ Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Nortriptyline. Depression [6A70-6A7Z] [13]
Nefazodone DM4ZS8M Major Decreased metabolism of Alfuzosin caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [15]
Selegiline DM6034S Moderate Additive hypotensive effects by the combination of Alfuzosin and Selegiline. Depression [6A70-6A7Z] [21]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Alfuzosin and Isocarboxazid. Depression [6A70-6A7Z] [21]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Alfuzosin and Escitalopram. Depression [6A70-6A7Z] [13]
Tranylcypromine DMGB5RE Moderate Additive hypotensive effects by the combination of Alfuzosin and Tranylcypromine. Depression [6A70-6A7Z] [21]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Alfuzosin and OPC-34712. Depression [6A70-6A7Z] [22]
Phenelzine DMHIDUE Moderate Additive hypotensive effects by the combination of Alfuzosin and Phenelzine. Depression [6A70-6A7Z] [21]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Clomipramine. Depression [6A70-6A7Z] [13]
Trazodone DMK1GBJ Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Trazodone. Depression [6A70-6A7Z] [29]
Amoxapine DMKITQE Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Amoxapine. Depression [6A70-6A7Z] [13]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Doxepin. Depression [6A70-6A7Z] [13]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Maprotiline. Depression [6A70-6A7Z] [13]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [13]
Deutetrabenazine DMUPFLI Moderate Additive CNS depression effects by the combination of Alfuzosin and Deutetrabenazine. Dystonic disorder [8A02] [30]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Alfuzosin and Ingrezza. Dystonic disorder [8A02] [31]
Stiripentol DMMSDOY Moderate Decreased metabolism of Alfuzosin caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [11]
Timolol DM3NXRU Moderate Additive hypotensive effects by the combination of Alfuzosin and Timolol. Essential hypertension [BA00] [32]
Phenoxybenzamine DM8KSQH Moderate Additive hypotensive effects by the combination of Alfuzosin and Phenoxybenzamine. Essential hypertension [BA00] [11]
Nadolol DMW6GVL Moderate Additive hypotensive effects by the combination of Alfuzosin and Nadolol. Essential hypertension [BA00] [32]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Solifenacin. Functional bladder disorder [GC50] [13]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Pentamidine. Fungal infection [1F29-1F2F] [13]
Ketoconazole DMPZI3Q Major Decreased metabolism of Alfuzosin caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [15]
Phentolamine DMXYJOB Moderate Additive hypotensive effects by the combination of Alfuzosin and Phentolamine. Gangrene [MC85] [11]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Alfuzosin and Cisapride. Gastro-oesophageal reflux disease [DA22] [13]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Sunitinib. Gastrointestinal stromal tumour [2B5B] [13]
Carteolol DMFMDOB Moderate Additive hypotensive effects by the combination of Alfuzosin and Carteolol. Glaucoma [9C61] [32]
Metipranolol DMJMVKI Moderate Additive hypotensive effects by the combination of Alfuzosin and Metipranolol. Glaucoma [9C61] [32]
Levobetaxolol DMSREPX Moderate Additive hypotensive effects by the combination of Alfuzosin and Levobetaxolol. Glaucoma [9C61] [32]
Levobunolol DMTNFCQ Moderate Additive hypotensive effects by the combination of Alfuzosin and Levobunolol. Glaucoma [9C61] [32]
Prazosin DMCD9YG Moderate Additive hypotensive effects by the combination of Alfuzosin and Prazosin. Heart failure [BD10-BD1Z] [11]
Carvedilol DMHTEAO Moderate Additive hypotensive effects by the combination of Alfuzosin and Carvedilol. Heart failure [BD10-BD1Z] [32]
Boceprevir DMBSHMF Major Decreased metabolism of Alfuzosin caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [15]
Telaprevir DMMRV29 Major Decreased metabolism of Alfuzosin caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [15]
Rifapentine DMCHV4I Moderate Increased metabolism of Alfuzosin caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [33]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Alfuzosin and Procarbazine. Hodgkin lymphoma [2B30] [21]
Delavirdine DM3NF5G Major Decreased metabolism of Alfuzosin caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [15]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Alfuzosin caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [15]
Cobicistat DM6L4H2 Major Decreased metabolism of Alfuzosin caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [15]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Alfuzosin and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [34]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Alfuzosin and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [35]
Etravirine DMGV8QU Moderate Increased metabolism of Alfuzosin caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [36]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [13]
Amprenavir DMLMXE0 Major Decreased metabolism of Alfuzosin caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [15]
Atazanavir DMSYRBX Major Decreased metabolism of Alfuzosin caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [15]
Ritonavir DMU764S Major Decreased metabolism of Alfuzosin caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [15]
Acebutolol DM0TI4U Moderate Additive hypotensive effects by the combination of Alfuzosin and Acebutolol. Hypertension [BA00-BA04] [32]
Moexipril DM26E4B Moderate Additive hypotensive effects by the combination of Alfuzosin and Moexipril. Hypertension [BA00-BA04] [37]
Bisoprolol DM3UZ95 Moderate Additive hypotensive effects by the combination of Alfuzosin and Bisoprolol. Hypertension [BA00-BA04] [32]
Captopril DM458UM Moderate Additive hypotensive effects by the combination of Alfuzosin and Captopril. Hypertension [BA00-BA04] [37]
Penbutolol DM4ES8F Moderate Additive hypotensive effects by the combination of Alfuzosin and Penbutolol. Hypertension [BA00-BA04] [32]
Trandolapril DM4L6EU Moderate Additive hypotensive effects by the combination of Alfuzosin and Trandolapril. Hypertension [BA00-BA04] [37]
Nebivolol DM7F1PA Moderate Additive hypotensive effects by the combination of Alfuzosin and Nebivolol. Hypertension [BA00-BA04] [32]
Fosinopril DM9NJ52 Moderate Additive hypotensive effects by the combination of Alfuzosin and Fosinopril. Hypertension [BA00-BA04] [37]
Doxazosin DM9PLRH Moderate Additive hypotensive effects by the combination of Alfuzosin and Doxazosin. Hypertension [BA00-BA04] [11]
Pindolol DMD2NV7 Moderate Additive hypotensive effects by the combination of Alfuzosin and Pindolol. Hypertension [BA00-BA04] [32]
Benazepril DMH1M9B Moderate Additive hypotensive effects by the combination of Alfuzosin and Benazepril. Hypertension [BA00-BA04] [37]
Labetalol DMK8U72 Moderate Additive hypotensive effects by the combination of Alfuzosin and Labetalol. Hypertension [BA00-BA04] [32]
Enalapril DMNFUZR Moderate Additive hypotensive effects by the combination of Alfuzosin and Enalapril. Hypertension [BA00-BA04] [37]
Perindopril DMOPZDT Moderate Additive hypotensive effects by the combination of Alfuzosin and Perindopril. Hypertension [BA00-BA04] [37]
Quinapril DMR8H31 Moderate Additive hypotensive effects by the combination of Alfuzosin and Quinapril. Hypertension [BA00-BA04] [37]
Conivaptan DM1V329 Moderate Decreased metabolism of Alfuzosin caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [11]
Propiomazine DMKY8V1 Moderate Additive hypotensive effects by the combination of Alfuzosin and Propiomazine. Insomnia [7A00-7A0Z] [22]
ITI-007 DMUQ1DO Moderate Additive hypotensive effects by the combination of Alfuzosin and ITI-007. Insomnia [7A00-7A0Z] [22]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Polyethylene glycol. Irritable bowel syndrome [DD91] [19]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Phenolphthalein. Irritable bowel syndrome [DD91] [13]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Alfuzosin and Crizotinib. Lung cancer [2C25] [38]
Ceritinib DMB920Z Major Decreased metabolism of Alfuzosin caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [15]
PF-06463922 DMKM7EW Moderate Increased metabolism of Alfuzosin caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [39]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Alfuzosin and Osimertinib. Lung cancer [2C25] [40]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Alfuzosin and Selpercatinib. Lung cancer [2C25] [19]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Alfuzosin and Halofantrine. Malaria [1F40-1F45] [41]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Alfuzosin and Chloroquine. Malaria [1F40-1F45] [42]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Alfuzosin and Hydroxychloroquine. Malaria [1F40-1F45] [42]
Quinine DMSWYF5 Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Quinine. Malaria [1F40-1F45] [13]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Primaquine. Malaria [1F40-1F45] [13]
Mefloquine DMWT905 Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Mefloquine. Malaria [1F40-1F45] [13]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [19]
Idelalisib DM602WT Major Decreased metabolism of Alfuzosin caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [15]
IPI-145 DMWA24P Moderate Decreased metabolism of Alfuzosin caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [11]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Arsenic trioxide. Mature B-cell lymphoma [2A85] [43]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Alfuzosin and Vemurafenib. Melanoma [2C30] [13]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and LGX818. Melanoma [2C30] [44]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Alfuzosin caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [19]
Danazol DML8KTN Moderate Decreased metabolism of Alfuzosin caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [11]
Propranolol DM79NTF Moderate Additive hypotensive effects by the combination of Alfuzosin and Propranolol. Migraine [8A80] [32]
Exjade DMHPRWG Moderate Decreased metabolism of Alfuzosin caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [45]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Alfuzosin and Panobinostat. Multiple myeloma [2A83] [46]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Thalidomide. Multiple myeloma [2A83] [15]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Fingolimod. Multiple sclerosis [8A40] [13]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Ozanimod. Multiple sclerosis [8A40] [47]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Alfuzosin caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [11]
Imatinib DM7RJXL Moderate Decreased metabolism of Alfuzosin caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [11]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Dasatinib. Myeloproliferative neoplasm [2A20] [13]
Modafinil DMYILBE Minor Increased metabolism of Alfuzosin caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [48]
Prochlorperazine DM53SRA Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Prochlorperazine. Nausea/vomiting [MD90] [13]
Promethazine DM6I5GR Moderate Additive hypotensive effects by the combination of Alfuzosin and Promethazine. Nausea/vomiting [MD90] [22]
Palonosetron DMBHMOX Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Palonosetron. Nausea/vomiting [MD90] [13]
Granisetron DMIUW25 Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Granisetron. Nausea/vomiting [MD90] [13]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Alfuzosin and Dolasetron. Nausea/vomiting [MD90] [13]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Ondansetron. Nausea/vomiting [MD90] [13]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Entrectinib. Non-small cell lung cancer [2C25] [15]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Alfuzosin and Levomethadyl Acetate. Opioid use disorder [6C43] [19]
Lofexidine DM1WXA6 Moderate Additive hypotensive effects by the combination of Alfuzosin and Lofexidine. Opioid use disorder [6C43] [13]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Rucaparib. Ovarian cancer [2C73] [13]
Dextropropoxyphene DM23HCX Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Dextropropoxyphene. Pain [MG30-MG3Z] [13]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Buprenorphine. Pain [MG30-MG3Z] [13]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Triclabendazole. Parasitic worm infestation [1F90] [13]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Alfuzosin and Safinamide. Parkinsonism [8A00] [21]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Alfuzosin and Rasagiline. Parkinsonism [8A00] [21]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Pimavanserin. Parkinsonism [8A00] [49]
Apomorphine DMX38HQ Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Apomorphine. Parkinsonism [8A00] [13]
Abametapir DM2RX0I Moderate Decreased metabolism of Alfuzosin caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [50]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Famotidine. Peptic ulcer [DA61] [15]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Alfuzosin and Lefamulin. Pneumonia [CA40] [51]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Alfuzosin caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [15]
Ritodrine DM4V6RL Moderate Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Ritodrine. Preterm labour/delivery [JB00] [18]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Degarelix. Prostate cancer [2C82] [19]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and ABIRATERONE. Prostate cancer [2C82] [19]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Nilutamide. Prostate cancer [2C82] [19]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Enzalutamide. Prostate cancer [2C82] [19]
Flutamide DMK0O7U Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Flutamide. Prostate cancer [2C82] [19]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Bicalutamide. Prostate cancer [2C82] [19]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Levomepromazine. Psychotic disorder [6A20-6A25] [13]
Fluphenazine DMIT8LX Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Fluphenazine. Psychotic disorder [6A20-6A25] [13]
Triflupromazine DMKFQJP Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Triflupromazine. Psychotic disorder [6A20-6A25] [13]
Tolazoline DMI40NL Moderate Additive hypotensive effects by the combination of Alfuzosin and Tolazoline. Pulmonary hypertension [BB01] [11]
Sorafenib DMS8IFC Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Sorafenib. Renal cell carcinoma [2C90] [13]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Alfuzosin and Gatifloxacin. Respiratory infection [CA07-CA4Z] [52]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Alfuzosin and Mesoridazine. Schizophrenia [6A20] [13]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Alfuzosin and Thioridazine. Schizophrenia [6A20] [13]
Aripiprazole DM3NUMH Moderate Additive hypotensive effects by the combination of Alfuzosin and Aripiprazole. Schizophrenia [6A20] [22]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Alfuzosin and Iloperidone. Schizophrenia [6A20] [13]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Paliperidone. Schizophrenia [6A20] [53]
Loxapine DM8AI9U Moderate Additive hypotensive effects by the combination of Alfuzosin and Loxapine. Schizophrenia [6A20] [22]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Alfuzosin and Haloperidol. Schizophrenia [6A20] [13]
Perphenazine DMA4MRX Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Perphenazine. Schizophrenia [6A20] [13]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Alfuzosin and Molindone. Schizophrenia [6A20] [22]
Chlorpromazine DMBGZI3 Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Chlorpromazine. Schizophrenia [6A20] [13]
Thiothixene DMDINC4 Moderate Additive hypotensive effects by the combination of Alfuzosin and Thiothixene. Schizophrenia [6A20] [22]
Clozapine DMFC71L Major Increased risk of prolong QT interval by the combination of Alfuzosin and Clozapine. Schizophrenia [6A20] [13]
Trifluoperazine DMKBYWI Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Trifluoperazine. Schizophrenia [6A20] [13]
Risperidone DMN6DXL Moderate Additive hypotensive effects by the combination of Alfuzosin and Risperidone. Schizophrenia [6A20] [53]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Alfuzosin and Amisulpride. Schizophrenia [6A20] [54]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Asenapine. Schizophrenia [6A20] [13]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Alfuzosin and Pimozide. Schizophrenia [6A20] [19]
Larotrectinib DM26CQR Moderate Decreased metabolism of Alfuzosin caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [15]
Armodafinil DMGB035 Minor Increased metabolism of Alfuzosin caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [48]
LEE011 DMMX75K Major Decreased metabolism of Alfuzosin caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [13]
Epirubicin DMPDW6T Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [13]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Alfuzosin and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [13]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [19]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [13]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Pitolisant. Somnolence [MG42] [19]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [13]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Adenosine. Supraventricular tachyarrhythmia [BC81] [13]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Alfuzosin caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [55]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Lenvatinib. Thyroid cancer [2D10] [13]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Alfuzosin and Cabozantinib. Thyroid cancer [2D10] [19]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Alfuzosin and Papaverine. Tonus and reflex abnormality [MB47] [56]
Tizanidine DMR2IQ4 Moderate Additive hypotensive effects by the combination of Alfuzosin and Tizanidine. Tonus and reflex abnormality [MB47] [11]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Tacrolimus. Transplant rejection [NE84] [13]
Astemizole DM2HN6Q Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Astemizole. Vasomotor/allergic rhinitis [CA08] [13]
Methdilazine DMAUHQX Moderate Additive hypotensive effects by the combination of Alfuzosin and Methdilazine. Vasomotor/allergic rhinitis [CA08] [22]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [13]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Alfuzosin and Procainamide. Ventricular tachyarrhythmia [BC71] [13]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Propafenone. Ventricular tachyarrhythmia [BC71] [13]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Alfuzosin and Flecainide. Ventricular tachyarrhythmia [BC71] [13]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Alfuzosin and Amiodarone. Ventricular tachyarrhythmia [BC71] [13]
⏷ Show the Full List of 236 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite E00392 104805 Diluent
Calcium hydrogenphosphate E00294 24441 Diluent
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 13 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Alfuzosin 10 mg tablet 10 mg 24 HR Extended Release Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7109).
2 Alfuzosin FDA Label
3 FDA Approved Drug Products: Alfuzosin Extended Release Tablets
4 BDDCS applied to over 900 drugs
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53.
8 In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2). Handb Exp Pharmacol. 2011;(201):325-71.
9 Cell membrane chromatography competitive binding analysis for characterization of 1A adrenoreceptor binding interactions. Anal Bioanal Chem. 2011 Jul;400(10):3625-33. doi: 10.1007/s00216-011-5026-z. Epub 2011 May 5.
10 The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994 Apr;45(4):703-8.
11 Product Information. Uroxatral (alfuzosin). sanofi-aventis , Bridgewater, NJ.
12 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
13 Canadian Pharmacists Association.
14 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
15 Cerner Multum, Inc. "Australian Product Information.".
16 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
17 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
18 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
19 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
20 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
21 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
22 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
23 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
24 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
25 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
26 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
27 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
28 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
29 Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]
30 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
31 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
32 Chrysant SG "Experience with terazosin administered in combination with other antihypertensive agents." Am J Med 80 (1986): 55-61. [PMID: 2872808]
33 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
34 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
35 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
36 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
37 Baba T, Tomiyama T, Takebe K "Enhancement by an ACE inhibitor of first-dose hypotension caused by an alpha-blocker." N Engl J Med 322 (1990): 1237. [PMID: 1970122]
38 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
39 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
40 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
41 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
42 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
43 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
44 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
45 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
46 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
47 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
48 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
49 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
50 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
51 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
52 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
53 Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9. [PMID: 7663034]
54 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
55 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
56 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]